男男性行为者中的HPV疫苗接种与肛门HPV感染
在258名HIV阴性及HIV阳性的男男性行为者中开展12个月7次随访研究,采用倾向评分校正的logistic与Cox回归分析。个体水平未发现疫苗接种与HPV 6/11/16/18感染或发病率相关,HPV型别水平分析显示接种与疫苗靶型别发病率降低相关(aHR=0.22),结论支持HPV疫苗对疫苗靶型别肛门感染的保护作用。
要点
- 个体水平分析未发现疫苗接种与HPV 6/11/16/18患病率或发病率相关。
- HPV型别水平分析显示接种与疫苗靶型别发病率降低相关(aHR=0.22)。
- 疫苗接种与非疫苗靶型别(同种内及跨种)发病率无显著关联。
核心结论
- 研究结果支持HPV疫苗接种可预防疫苗靶型别HPV的肛门新发感染,因此应鼓励男男性行为者接种HPV疫苗。
研究设计与样本
- 研究纳入258名HIV阴性及HIV阳性的男男性行为者(年龄18.2-71.7岁,其中69人为HIV阳性),在12个月内进行7次访视,由护士采集肛门样本并以聚合酶链反应检测HPV。
主要发现
- 基线时23.3%的参与者已接种疫苗。
- 个体水平分析:疫苗接种与HPV 6/11/16/18患病率无关联(n=250,aOR=1.12,95%CI=0.56-2.22),与发病率亦无关联(n=152,aHR=0.34,95%CI=2.19×10^-18-1.38)。
- HPV型别水平分析:疫苗接种与HPV 6/11/16/18患病率无关联(n=1000,aOR=0.99,95%CI=0.57-1.71),但与HPV 6/11/16/18发病率降低相关(n=754,aHR=0.22,95%CI=6.01×10^-18-0.79)。
- 疫苗接种与同种内HPV型别发病率无关联(n=2299,aHR=0.76,95%CI=0.42-1.24),与跨种HPV型别发病率亦无关联(n=3774,aHR=1.28,95%CI=0.89-1.85)。
- 按HIV状态分层结果相似。
临床怎么用
- 作者结论认为研究结果支持HPV疫苗接种可预防疫苗靶型别HPV的肛门新发感染,并应鼓励男男性行为者接种HPV疫苗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Gay, bisexual, and other men who have sex with men (gbMSM) have a higher risk of human papillomavirus (HPV) infection and related diseases and would benefit from preventive measures such as HPV vaccination. We assessed the association between HPV vaccination and anal HPV infection in HIV-negative gbMSM and gbMSM living with HIV from the Lubricant Investigation in Men to Inhibit Transmission of HPV Infection study. METHODS: Participants attended 7 visits over 12 months where they provided a nurse-collected anal sample and self-completed a questionnaire on risk factors and HPV vaccination. Samples were tested for HPV using polymerase chain reaction assays. We assessed the association with HPV vaccination and anal HPV prevalence and incidence using logistic and Cox regression, respectively. Analyses at the individual- (unit of analysis = participant) and HPV-level (unit of analysis = HPV type) considered vaccine-targeted types (any of HPVs 6/11/16/18) as the outcome. To assess construct validity, we repeated analyses considering incidence of non-vaccine-targeted (within- and cross-species) HPV types at the HPV-level. Estimates were adjusted for a propensity score to predict cumulative HPV positivity based on selected study and participant characteristics. RESULTS: Of 258 enrolled participants (18.2-71.7 years; 69 being HIV-positive), 23.3 % were vaccinated at baseline. At the individual-level, there was no association between vaccination and HPVs 6/11/16/18 prevalence (n = 250, aOR = 1.12, 95 % CI = 0.56-2.22) or incidence (n = 152, aHR = 0.34, 95 % CI = 2.19 × 10-18-1.38). At the HPV-level, while there was no association with HPVs 6/11/16/18 prevalence (n = 1000, aOR = 0.99, 95 % CI = 0.57-1.71), vaccination was associated with a reduction in HPVs 6/11/16/18 incidence (n = 754, aHR = 0.22, 95 % CI = 6.01 × 10-18-0.79). Vaccination was not associated with incidence of within-species (n = 2299, aHR = 0.76, CI = 0.42-1.24) or cross-species (n = 3774, aHR = 1.28, CI = 0.89-1.85) HPV types. Results were similar by HIV status. CONCLUSION: Our findings support that HPV vaccination protects against incident anal infection of vaccine-targeted HPV types, thus, gbMSM should be encouraged to get vaccinated against HPV.
引用
- Kassam P, El-Zein M, Tota JE, et al. HPV vaccination and anal HPV infection in gay, bisexual, and other men who have sex with men. Vaccine. 2024. PMID: 39708517. doi:10.1016/j.vaccine.2024.126644
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。